DOCSLIB.ORG

Molecular Insights Into the Hibernation of the Central Bearded Dragon

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Insights Into the Hibernation of the Central Bearded Dragon Waking the sleeping dragon: molecular insights into the hibernation of the central bearded dragon by Alexander Capraro A thesis in the fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) in Biochemistry and Molecular Genetics School of Biochemistry and Biomolecular Sciences Faculty of Science University of New South Wales February 2020 Thesis/Dissertation Sheet Surname/Family Name : CAPRARO Given Name/s : Alexander Abbreviation for degree as give in the University calendar : PhD Faculty : Science School : Biotechnology and Biomolecular Sciences Waking the sleeping dragon: molecular insight into the hibernation of Thesis Title : the central bearded dragon Abstract: One of the most profound adaptive strategies employed by animals in response to changes in environmental conditions is hibernation. Hibernation is an extended state of hypometabolism and dormancy induced to survive the low food availability and high physiological stress associated with winter. During the long periods of dormancy, hibernators experience changes in core biological processes, including drastic reductions in basal metabolic rate, core body temperature, oxygen consumption, heart rate and brain activity. Stress response pathways are also modulated to mitigate physiological challenges that would otherwise prove lethal to the animal. Modulation of these responses requires tightly controlled regulatory processes. While hibernation is a common response utilised by diverse lineages of animals, molecular investigations into this phenomenon have primarily focused on mammalian systems. In this thesis, I investigated the molecular mechanisms involved in the hibernation of the Australian central bearded dragon (Pogona vitticeps) using high-throughput sequencing technologies. The transcriptomic and proteomic changes in three tissues; brain, heart and skeletal muscle, during hibernation and at two time points post-arousal were examined. Hibernation was associated with the induction of common and tissue-specific stress response pathways in addition to the modulation of regulatory processes. I studied the role of microRNAs (miRNA) in mediating the changes in gene expression that are characteristic of the three tissues during hibernation and four days post-arousal. Cellular metabolism and neuroprotection of the brain emerged as key pathways under miRNA-mediated regulation. The DNA methylation dynamics in brain and skeletal muscle during hibernation and at two time points post-arousal were also examined. Alterations in DNA methylation were associated with changes in gene expression that lead to increased neuroprotection of the brain and a reduced potential for atrophy in skeletal muscle. Collectively, the data presented in this thesis shows that the precise interplay of multiple gene regulatory mechanisms is crucial in modulating the large-scale changes in cellular physiology and function observed in hibernating bearded dragons. Furthermore, the data presented bridges the gap between mammalian and reptilian hibernation and suggests they are more similar than previously thought. Declaration relating to disposition of project thesis/dissertation I hereby grant to the University of New South Wales or its agents a non-exclusive licence to archive and to make available (including to members of the public) my thesis or dissertation in whole or in part in the University libraries in all forms of media, now or here after known. I acknowledge that I retain all intellectual property rights which subsist in my thesis or dissertation, such as copyright and patent rights, subject to applicable law. I also retain the right to use all or part of my thesis or dissertation in future works (such as articles or books). ……………………………………………………… ……………………………………………………… Signature Date The University recognises that there may be exceptional circumstances requiring restrictions on copying or conditions on use. Requests for restriction for a period of up to 2 years can be made when submitting the final copies of your thesis to the UNSW Library. Requests for a longer period of restriction may be considered in exceptional circumstances and require the approval of the Dean of Graduate Research. i ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………………………….............. Date …………………………………………….............. ii COPYRIGHT STATEMENT ‘I hereby grant the University of New South Wales or its agents a non-exclusive licence to archive and to make available (including to members of the public) my thesis or dissertation in whole or part in the University libraries in all forms of media, now or here after known. I acknowledge that I retain all intellectual property rights which subsist in my thesis or dissertation, such as copyright and patent rights, subject to applicable law. I also retain the right to use all or part of my thesis or dissertation in future works (such as articles or books).’ ‘For any substantial portions of copyright material used in this thesis, written permission for use has been obtained, or the copyright material is removed from the final public version of the thesis.’ Signed ……………………………………………........................... Date …………………………………………….............................. AUTHENTICITY STATEMENT ‘I certify that the Library deposit digital copy is a direct equivalent of the final officially approved version of my thesis.’ Signed ……………………………………………........................... Date …………………………………………….............................. iii Inclusion of publications statement UNSW is supportive of candidates publishing their research results during their candidature as detailed in the UNSW Thesis Examination Procedure. Publications can be used in their thesis in lieu of a Chapter if: • The candidate contributed greater than 50% of the content in the publication and is the “primary author”, i.e. the candidate was responsible primarily for the planning, execution and preparation of the work for publication • The candidate has approval to include the publication in their thesis in lieu of a Chapter from their supervisor and Postgraduate Coordinator. • The publication is not subject to any obligations or contractual agreements with a third party that would constrain its inclusion in the thesis Please indicate whether this thesis contains published material or not: ☐ This thesis contains no publications, either published or submitted for publication Some of the work described in this thesis has been published and it has been documented ☐ in the relevant Chapters with acknowledgement This thesis has publications (either published or submitted for publication) incorporated ☒ into it in lieu of a chapter and the details are presented below CANDIDATE’S DECLARATION I declare that: • I have complied with the UNSW Thesis Examination Procedure • where I have used a publication in lieu of a Chapter, the listed publication(s) below meet(s) the requirements to be included in the thesis. Candidate’s Name Signature Date (dd/mm/yy) POSTGRADUATE COORDINATOR’S DECLARATION I declare that: • the information below is accurate • where listed publication(s) have been used in lieu of Chapter(s), their use complies with the UNSW Thesis Examination Procedure • the minimum requirements for the format of the thesis have been met. PGC’s Name PGC’s Signature Date (dd/mm/yy) iv Details of publication #1: Full title: Waking the sleeping dragon: gene expression profiling reveals adaptive strategies of the hibernating reptile Pogona vitticeps Authors: Alexander Capraro, Denis O’Meally, Shafagh A. Waters, Hardip R. Patel, Arthur Georges and Paul D. Waters Journal or book name: BMC Genomics Volume/page numbers: 20:460 Date published: 6/6/2019 Status Published X Accepted and in In progress press (submitted) The Candidate’s Contribution to the Work Alexander Capraro contributed to the design of the study, performed the experiments and computational analysis of sequencing and mass spectrometry data, and wrote the paper. Location of the work in the thesis and/or how the work is incorporated in the thesis: This publication will be used in lieu of chapter 2. PRIMARY SUPERVISOR’S DECLARATION I declare that: • the information above is accurate • this has been discussed with the PGC and it is agreed that this publication can be included in this thesis in lieu of a Chapter • All of the co-authors of the publication have reviewed the above information and have agreed to its veracity by signing a ‘Co-Author Authorisation’ form. Primary Supervisor’s name Primary Supervisor’s signature Date (dd/mm/yy) v Details of publication #2: Full title: The role of microRNAs in regulating neuroprotection in the brain of hibernating central bearded dragons Authors: Alexander Capraro, Denis O’Meally, Shafagh A. Waters, Hardip R. Patel, Arthur Georges and Paul D. Waters Journal or book name: BMC Biology/BMC Genome
Load more

Recommended publications
  • 32-3099: PRKAB1 Recombinant Protein Description
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-3099: PRKAB1 Recombinant Protein Alternative Name : AMPK,HAMPKb,5'-AMP-activated protein kinase subunit beta-1,AMPK subunit beta-1,AMPKb,PRKAB1. Description Source : E.coli. PRKAB1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 293 amino acids (1-270 a.a.) and having a molecular mass of 32.8 kDa. The PRKAB1 is fused to a 23 amino acid His Tag at N- Terminus and purified by proprietary chromatographic techniques. 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) hinders protein, carbohydrate and lipid biosynthesis, in addition to cell growth and proliferation. AMPK is a heterotrimer comprised of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK acts via direct phosphorylation of metabolic enzymes, and longer-term effects by phosphorylation of transcription regulators. PRKAB1 is a regulator of cellular polarity by remodeling the actin cytoskeleton; most likely by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex compiles, through its C-terminus that joins alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3). Product Info Amount : 5 µg Purification : Greater than 85% as determined by SDS-PAGE. The PRKAB1 protein solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, Content : 10% glycerol and 1mM DTT. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time.
    [Show full text]
  • Human Kinome Profiling Identifies a Requirement for AMP-Activated
    Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection Laura J. Terrya, Livia Vastagb,1, Joshua D. Rabinowitzb, and Thomas Shenka,2 aDepartment of Molecular Biology and bDepartment of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544 Contributed by Thomas Shenk, January 11, 2012 (sent for review December 29, 2011) Human cytomegalovirus (HCMV) modulates numerous cellular (7). Thus, the connections between AMPK activity and metabolic signaling pathways. Alterations in signaling are evident from the changes during HCMV infection have remained unclear. broad changes in cellular phosphorylation that occur during HCMV We confirmed the requirement for AMPK during infection, infection and from the altered activity of multiple kinases. Here we and we show that an AMPK antagonist, compound C, blocks report a comprehensive RNAi screen, which predicts that 106 cellular HCMV-induced changes to glycolysis and inhibits viral gene kinases influence growth of the virus, most of which were not expression. These studies argue that AMPK or a related, com- previously linked to HCMV replication. Multiple elements of the pound C-sensitive kinase is an essential contributor to metabolic AMP-activated protein kinase (AMPK) pathway scored in the screen. changes initiated by HCMV and provide unique insight into As a regulator of carbon and nucleotide metabolism, AMPK is poised potential antiviral strategies. to activate many of the metabolic pathways induced by HCMV infection. An AMPK inhibitor, compound C, blocked a substantial Results portion of HCMV-induced metabolic changes, inhibited the accumu- HumanKinomeScreenIdentifies Putative Effectors of HCMV Replication. lation of all HCMV proteins tested, and markedly reduced the We conducted an siRNA screen of the human kinome to perform an production of infectious progeny.
    [Show full text]
  • Down Regulation of Membrane-Bound Neu3 Constitutes a New
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Publications of the IAS Fellows IJC International Journal of Cancer Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells Chandan Mandal1, Cristina Tringali2, Susmita Mondal1, Luigi Anastasia2, Sarmila Chandra3, Bruno Venerando2 and Chitra Mandal1 1 Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, A Unit of Council of Scientific and Industrial Research, Govt of India, 4, Raja S. C. Mullick Road, Kolkata 700032, India 2 Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, and IRCCS Policlinico San Donato, San Donato, Milan, Italy 3 Department of Hematology, Kothari Medical Centre, Kolkata 700027, India Membrane-linked sialidase Neu3 is a key enzyme for the extralysosomal catabolism of gangliosides. In this respect, it regulates pivotal cell surface events, including trans-membrane signaling, and plays an essential role in carcinogenesis. In this report, we demonstrated that acute lymphoblastic leukemia (ALL), lymphoblasts (primary cells from patients and cell lines) are characterized by a marked down-regulation of Neu3 in terms of both gene expression (230 to 40%) and enzymatic activity toward ganglioside GD1a (225.6 to 30.6%), when compared with cells from healthy controls. Induced overexpression of Neu3 in the ALL-cell line, MOLT-4, led to a significant increase of ceramide (166%) and to a parallel decrease of lactosylceramide (255%). These events strongly guided lymphoblasts to apoptosis, as we assessed by the decrease in Bcl2/ Bax ratio, the accumulation of Neu3 transfected cells in the sub G0–G1 phase of the cell cycle, the enhanced annexin-V positivity, the higher cleavage of procaspase-3.
    [Show full text]
  • Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling
    UC Davis UC Davis Previously Published Works Title Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling. Permalink https://escholarship.org/uc/item/0nk8n7xb Journal Scientific reports, 6(1) ISSN 2045-2322 Authors Arabyan, Narine Park, Dayoung Foutouhi, Soraya et al. Publication Date 2016-07-08 DOI 10.1038/srep29525 Peer reviewed eScholarship.org Powered by the California Digital Library University of California www.nature.com/scientificreports OPEN Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling Received: 09 February 2016 Narine Arabyan1, Dayoung Park2, Soraya Foutouhi1, Allison M. Weis1, Bihua C. Huang1, Accepted: 17 June 2016 Cynthia C. Williams2, Prerak Desai1,†, Jigna Shah1,‡, Richard Jeannotte1,3,§, Nguyet Kong1, Published: 08 July 2016 Carlito B. Lebrilla2,4 & Bart C. Weimer1 Complex glycans cover the gut epithelial surface to protect the cell from the environment. Invasive pathogens must breach the glycan layer before initiating infection. While glycan degradation is crucial for infection, this process is inadequately understood. Salmonella contains 47 glycosyl hydrolases (GHs) that may degrade the glycan. We hypothesized that keystone genes from the entire GH complement of Salmonella are required to degrade glycans to change infection. This study determined that GHs recognize the terminal monosaccharides (N-acetylneuraminic acid (Neu5Ac), galactose, mannose, and fucose) and significantly (p < 0.05) alter infection. During infection, Salmonella used its two GHs sialidase nanH and amylase malS for internalization by targeting different glycan structures. The host glycans were altered during Salmonella association via the induction of N-glycan biosynthesis pathways leading to modification of host glycans by increasing fucosylation and mannose content, while decreasing sialylation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Characterization of the Human Sialidase Neu4 Gene Promoter
    Turkish Journal of Biology Turk J Biol (2014) 38: 574-580 http://journals.tubitak.gov.tr/biology/ © TÜBİTAK Research Article doi:10.3906/biy-1401-63 Characterization of the human sialidase Neu4 gene promoter 1, 2 Volkan SEYRANTEPE *, Murat DELMAN 1 Department of Molecular Biology and Genetics, İzmir Institute of Technology, Urla İzmir, Turkey 2 Biotechnology and Bioengineering Graduate Program, İzmir Institute of Technology, Urla, İzmir, Turkey Received: 21.01.2014 Accepted: 08.05.2014 Published Online: 05.09.2014 Printed: 30.09.2014 Abstract: There are 4 different sialidases that have been described in humans: lysosomal (Neu1), cytoplasmic (Neu2), plasma membrane (Neu3), and lysosomal/mitochondrial (Neu4). Previously, we have shown that Neu4 has a broad substrate specificity and is active against glyco-conjugates, including GM2 ganglioside, at the acidic pH of 3.2. An overexpression of Neu4 in transfected neuroglia cells from a Tay–Sachs patient shows a clearance of accumulated GM2, indicating the biological importance of Neu4. In this paper, we aimed to characterize a minimal promoter region of the human Neu4 gene in order to understand the molecular mechanism regulating its expression. We cloned 7 different DNA fragments from the human Neu4 promoter region into luciferase expression vectors for a reporter assay and also performed an electrophoretic mobility shift assay to demonstrate the binding of transcription factors. We demonstrated that –187 bp upstream of the Neu4 gene is a minimal promoter region for controlling transcription from the human Neu4 gene. The electrophoretic mobility shift assay showed that the minimal promoter region recruits a c-myc transcription factor, which might be responsible for regulation of Neu4 gene transcription.
    [Show full text]
  • Brain Lipid Profiling of Triply Mouse Model with the Deficiencies of Sialidase Neu1, Neu4 and Β-Hexosaminidase a Enzymes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by DSpace@IZTECH Institutional Repository BRAIN LIPID PROFILING OF TRIPLY MOUSE MODEL WITH THE DEFICIENCIES OF SIALIDASE NEU1, NEU4 AND β-HEXOSAMINIDASE A ENZYMES A Thesis Submitted to the Graduate School of Engineering and Sciences of İzmir Institute of Technology in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE in Molecular Biology and Genetics by Zehra Kevser PEKMEZCİ December 2011 İZMİR We approve the thesis of Zehra Kevser PEKMEZCİ ____________________________ Assoc. Prof. Dr. Volkan SEYRANTEPE Supervisor _________________________ Assoc. Prof. Dr. Yusuf BARAN Committee Member ______________________________ Assoc. Prof. Dr. Şermin GENÇ Committee Member 20 December 2011 _________________________________ ______________________________ Assoc. Prof. Dr. Ahmet KOÇ Prof. Dr. R. Tuğrul SENGER Head of the Department of Molecular Dean of the Graduate School of Biology and Genetics Engineering and Sciences ACKNOWLEDGMENTS First of all, I would like to indicate my deepest regards and thanks to my supervisor Assoc. Prof. Dr. Volkan SEYRANTEPE for his encouragement, understanding, guidance, and excellent support during my graduate studies. I would like to thank to Assist. Prof. Dr. Alper Arslanoğlu to let me use his laboratory during my thesis studies. And I would also like to thank to Assist. Prof. Dr. Ayten Nalbant, Assist. Prof. Dr. Bünyamin Akgül, Assoc. Prof. Dr. Sami Doğanlar, Assoc. Prof. Dr. Ahmet Koç, Prof. Dr. Serdar Özçelik and Assoc. Prof. Dr. Mehtap Demirağ to let me use their laboratory during my studies. Also I would like to express my grateful thanks to my committee members Assoc.
    [Show full text]
  • Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in Vitro and in Vivo
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genetik Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in vitro and in vivo - Towards Response Prediction in Cancer Therapy with Kinase Inhibitors Michaela Bairlein Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ. -Prof. Dr. K. Schneitz Prüfer der Dissertation: 1. Univ.-Prof. Dr. A. Gierl 2. Hon.-Prof. Dr. h.c. A. Ullrich (Eberhard-Karls-Universität Tübingen) 3. Univ.-Prof. A. Schnieke, Ph.D. Die Dissertation wurde am 07.01.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 19.04.2010 angenommen. FOR MY PARENTS 1 Contents 2 Summary ................................................................................................................................................................... 5 3 Zusammenfassung .................................................................................................................................................... 6 4 Introduction .............................................................................................................................................................. 8 4.1 Cancer ..............................................................................................................................................................
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Cell Surface Sialylated N-Glycan Alterations During Development
    REVIEW ARTICLE Eur J Biol 2017; 76(2): 79-88 Cell Surface Sialylated N-Glycan Alterations during Development Sabire Karacali Ege Universiy, Faculty of Science, Department of Biology, Izmir, Turkey Please cite this article as: Karacali S. Cell Surface Sialylated N-Glycan Alterations during Development. Eur J Biol 2017; 76(2): 79-88 ABSTRACT This brief survey focuses on the comparison of sialylated N-glycans of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs) and of differentiated cells. In addition, the impact of sialic acid (Sia) deficiency on cell surfaces during development is summarized. The most common Sia is N-acetylneuraminic acid (Neu5Ac). The branched structures of complex- and hybrid- type N-glycans are the carrier for Sia. Transmembrane adhesive proteins, voltage-gated ion channels and many ligand-activated receptors are some examples of heavily sialylated N-glycan bearing membrane proteins. Their oligosaccharide extensions provide an important contribution to glycocalyx glycans. ESCs and iPSCs are characterized with high mannose-type and biantennary complex-type core structures. Two branches terminate with α2,6- linked Sia. MSCs contain high mannose, hybrid- and complex- type N-glycans. Linear poly-N-acetyllactosamine (poly-Galβ1-4GlcNAc, poly-LacNAc) chains are the characteristic structures. Both α2,3- and α2,6- linked Sias are seen in a species-specific manner in MSCs. α2,6- linked Sia is probably a marker associated with the multipotency of human MSCs. Differentiated healthy cells contain the most abundant 2-branched complex structures. The bisecting branch on the core structure appears as a differentiation marker. poly-LacNAc chains are terminated with α2,3- and α2,6- linked Sia, with the former being higher.
    [Show full text]
  • Characterization of Transgenic Mouse Model of Humanized Sialidase
    TRANSGENIC MOUSE MODEL OF HUMANIZED SIALIDASE CHRACTERIZATION OF TRANSGENIC MOUSE MODEL OF HUMANIZED SIALIDSAE By Ghada A. Tarbah, B.Sc. A Thesis submitted to the School of Graduate Studies in Partial fulfillment of the Requirements for the Degree Master of Science McMaster University © Copyright by Ghada Tarbah, June 2009 MASTER OF SCIENCE (2008) McMaster University (Biology) Hamilton, Ontario M.Sc. thesis - G. Tarbah McMaster - Biology TITLE: Characterization of Transgenic Mouse Model of Humanized Sialidase AUTHOR: Ghada A. Tarbah, B.Sc. SUPERVISOR: Suleiman Igdoura, PhD, Associate Professor, McMaster University Number of Pages: XI, 59 ii M.Sc. thesis - G. Tarbah McMaster - Biology ABSTRACT Ganglosidoses are a group of fatal neurological disorders which primarily affect children. Pathologically, these disorders need more characterization. The recent development of mouse models of these diseases makes it possible to identify progressive pathological changes within the CNS at the molecular level. Tay Sachs disease is a lysosomal storage disorder characterized by accumulation of GM2 Ganglioside. Targeted Knockout of ~-hexosaminidase A (hex a) was generated as a mouse model of Tay Sachs disease; however, the mouse showed little clinical phenotype. The molecular mechanism which allows the hexa-/- mouse to escape the disease involves a metabolic bypass facilitated by lysosomal Sialidase (neu l). In this study we hypothesize that the reason humans have the infantile Tay-Sachs whereas mice do not, is a difference in specificity between human and mouse sialidases. This specificity difference makes the human sialidase unable to hydrolyze GM2 to GA2, which leads to the accumulation of GM2 in neurons and consequently a resulting Tay-Sachs phenotype.
    [Show full text]
  • A1248-Phospho-Ampkβ1 (Ser182)
    BioVision 12/16 For research use only Phospho-AMPKβ1 (Ser182) Antibody CATALOG NO: A1248-100 100 µl ALTERNATE NAMES: PRKAB1; AMPK; 5'-AMP-activated protein kinase subunit beta-1; AMPK subunit beta-1; AMPKb AMOUNT: 100 µl (1 mg/ml) Western Blot analysis of COLO205 cells using Phospho- IMMUNOGEN: Synthesized peptide derived from human AMPKβ1 around the AMPKbeta1 (Ser182) Polyclonal phosphorylation site of S182 (120-200aa) Antibody MOL. WEIGHT 38 kDa HOST/ISOTYPE: Rabbit IgG SPECIES REACTIVITY: Human, Mouse, Rat SPECIFICITY: Phospho-AMPKβ1 (S182) Polyclonal Antibody detects endogenous levels of AMPKβ1 protein only when phosphorylated at S182. PURIFICATION: The antibody was affinity-purified from rabbit antiserum by affinity- chromatography using epitope-specific immunogen FORM: Liquid FORMULATION: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% RELATED PRODUCTS: sodium azide STORAGE CONDITIONS: Store at -20°C. Avoid repeated freeze/thaw cycles. AMPKα Antibody (Cat. No. 3113-100) AMPKα1 Antibody (Cat. No. 3110-100) DESCRIPTION: Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating AMPKβ Antibody (Cat. No. 3108-100) cellular energy metabolism. In response to reduction of intracellular AMPKγ Antibody (Cat. No. 3109-100) ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, AMPK1 Antibody (Cat. No. 3112-100) carbohydrate and lipid biosynthesis, as well as cell growth and AMPK2 Antibody (Cat. No. 3118-100) proliferation. AMPK acts via direct phosphorylation of metabolic AMPK⍺1 Antibody (Cat. No. 3951-100) enzymes, and by longer-term effects via phosphorylation of transcription regulators.
    [Show full text]